Japan – Eisai to Showcase Alzheimer’s Disease Portfolio with More Than 50 Presentations at the Alzheimer’s Association International Conference(R) 2026 (AAIC(R))

Eisai Co., Ltd. revealed today the business will provide the current findings from its Alzheimer’s illness (ADVERTISEMENT) research study, consisting of lecanemab (trademark name: LEQEMBI ®), our anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s illness (ADVERTISEMENT) and anti-MTBR (microtubule binding area) tau antibody …